KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Current Deferred Revenue (2016 - 2022)

Historic Current Deferred Revenue for Bio-Rad Laboratories (BIO) over the last 13 years, with Q4 2022 value amounting to $71.9 million.

  • Bio-Rad Laboratories' Current Deferred Revenue rose 126.76% to $71.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $71.9 million, marking a year-over-year increase of 126.76%. This contributed to the annual value of $71.9 million for FY2022, which is 126.76% up from last year.
  • Per Bio-Rad Laboratories' latest filing, its Current Deferred Revenue stood at $71.9 million for Q4 2022, which was up 126.76% from $71.0 million recorded in Q4 2021.
  • Over the past 5 years, Bio-Rad Laboratories' Current Deferred Revenue peaked at $71.9 million during Q4 2022, and registered a low of $37.3 million during Q4 2018.
  • Moreover, its 5-year median value for Current Deferred Revenue was $45.6 million (2019), whereas its average is $49.1 million.
  • As far as peak fluctuations go, Bio-Rad Laboratories' Current Deferred Revenue surged by 3100.44% in 2020, and later soared by 126.76% in 2022.
  • Quarter analysis of 5 years shows Bio-Rad Laboratories' Current Deferred Revenue stood at $37.3 million in 2018, then grew by 22.79% to $45.8 million in 2019, then surged by 31.0% to $60.0 million in 2020, then grew by 18.33% to $71.0 million in 2021, then rose by 1.27% to $71.9 million in 2022.
  • Its Current Deferred Revenue stands at $71.9 million for Q4 2022, versus $71.0 million for Q4 2021 and $60.0 million for Q4 2020.